News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

InSite Vision (ISV) Announces The Issuance Of Broad U.S. Patent Covering Bromfenac Formulations In Durasite®


7/16/2014 8:10:35 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (OTCBB:INSV) today announced that the United States Patent and Trademark Office (USPTO) has issued a U.S. Patent No. 8,778,999 covering Bromfenac Non-Steroidal Ophthalmic Compositions Formulated in DuraSite. The allowed patent contains both composition and method of treatment claims that will broadly cover all of InSite’s bromfenac product candidates, including BromSite™ (bromfenac 0.075% ophthalmic solution formulated in DuraSite, ISV-303) for the treatment of inflammation and prevention of pain post cataract surgery. Additional bromfenac-containing products in InSite’s pipeline covered under this patent include: ISV-101 (bromfenac 0.01%-0.04% ophthalmic solution formulated in DuraSite) for the treatment of dry eye disease, back-of-the eye BromSite indications, such as the prevention of cystoid macular edema (CME), as well as the combination of bromfenac and dexamethasone containing products such as BromDex™ (ISV-504). Due to USPTO delays, the patent term was extended by 155 days to provide protection for bromfenac formulations in DuraSite to August 2029.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES